Abstract Number: 0946 • ACR Convergence 2024
Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations
Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of peripheral monocytes (PM) is not sufficient to rescue disease in RA…Abstract Number: 1589 • ACR Convergence 2024
Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis
Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement. We have asked whether whole skin gene expression may…Abstract Number: 1660 • ACR Convergence 2024
Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals
Background/Purpose: Elevated levels of RA-associated autoantibodies (ACPA, RF) prior to the clinical onset of inflammatory arthritis (IA) define a state of risk for future development…Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…Abstract Number: 1771 • ACR Convergence 2024
Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…Abstract Number: 1797 • ACR Convergence 2024
Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…Abstract Number: 2096 • ACR Convergence 2024
A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…Abstract Number: 2418 • ACR Convergence 2024
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…Abstract Number: 1661 • ACR Convergence 2023
Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin
Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…Abstract Number: 1762 • ACR Convergence 2023
Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls
Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…Abstract Number: 2342 • ACR Convergence 2023
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…Abstract Number: 2540 • ACR Convergence 2023
The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response
Background/Purpose: Rheumatoid arthritis (RA) is a remarkably heterogeneous autoimmune disease whose clinical outcomes with disease-modifying antirheumatic drugs (DMARDs) remain unpredictable. The aim of this study…Abstract Number: 2586 • ACR Convergence 2023
A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis
Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…Abstract Number: 0075 • ACR Convergence 2023
Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)
Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. The…
